Angiogenic factors as predictors of survival in patients with bone sarcomas
- 作者: Merkureva О.N.1,2, Prishchep P.L.2, Kuznetsov I.N.1, Sokolov N.Y.3, Varfolomeeva S.R.2, Kushlinskii N.Е.1,2
-
隶属关系:
- Russian University of Medicine
- N.N. Blokhin National Medical Research Center of Oncology
- S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center
- 期: 卷 27, 编号 10 (2024)
- 页面: 19-26
- 栏目: Medical chemistry
- URL: https://ogarev-online.ru/1560-9596/article/view/270956
- DOI: https://doi.org/10.29296/25877313-2024-10-03
- ID: 270956
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
订阅存取
详细
Introduction. Primary bone sarcomas are relatively rare neoplasms. They occur predominantly in adolescents and young adults, are characterized by an aggressive clinical course and a high metastatic potential, have a poor prognosis. In this regard, the problem of stratifying the risk of metastasis and death in order to select the optimal treatment tactics always remains relevant. The study of such markers as endostatin, vascular endothelial growth factor (VEGF), insulin-like growth factors IGF-1, IGF-2 as potentially informative predictors of survival in patients with bone sarcomas is pathogenetically determined by their involvement in the processes of tumor growth and metastasis.
Aim – to analyze the relationship between pre-treatment serum levels of endostatin, VEGF, IGF-1 and IGF-2 with overall survival rates in patients with bone sarcomas.
Material and methods. An analysis of overall survival rates was carried out in 134 patients with malignant bone tumors aged from 1 to 73 years (Me=27.0 years; Q1–Q3: 18.0 – 43.0 years), among them 87 men (64.9%) and 47 women (35.1%). All patients comprised 4 groups: osteosarcoma (n=58), undifferentiated pleomorphic sarcoma (n=5), Ewing sarcoma (n=29), chondrosarcoma (n=42). In all of them, before the start of specific antitumor treatment, the levels of endostatin, VEGF, IGF-1, and IGF-2 in the blood serum were determined using enzyme immunoassay. The follow-up period ranged from 1 to 229 months (Me=23.0 months; Q1–Q3: 10.0–121.0 months). To analyze overall survival, life tables and Kaplan–Meier curves were constructed. The effect of the studied serum markers on survival rates was assessed using the logrank test and Cox proportional hazards regression model.
Results. During observation, death occurred in 51 patients (38.1%). In the group of deceased patients, serum levels of endostatin and IGF-2 were statistically significantly increased compared to the group of surviving patients (p<0.001 and p=0.011, respectively). Kaplan-Meier survival analysis using the logrank test revealed statistically significant differences in overall survival between the four groups of patients with different serum levels of endostatin, IGF-1 and IGF-2. The Cox regression method established the prognostic significance of endostatin as a predictor of overall survival (HR=1.012; p=0.013).
Conclusion. Endostatin, IGF-1, IGF-2 can serve as predictors of overall survival of patients with bone sarcomas.
关键词
作者简介
О. Merkureva
Russian University of Medicine; N.N. Blokhin National Medical Research Center of Oncology
编辑信件的主要联系方式.
Email: merkureva.o.n@gmail.com
ORCID iD: 0000-0001-6744-005X
Specialist in Laboratory Medicine, Post-graduate Student
俄罗斯联邦, 4 Dolgorukovskaya ul., Moscow, 127006; 24 Kashirskoye shosse, Moscow, 115522P. Prishchep
N.N. Blokhin National Medical Research Center of Oncology
Email: Paulig92@mail.ru
ORCID iD: 0000-0003-0810-8238
Post-graduate Student, Pediatric Oncologist, Research Institute of Pediatric Hematology and Oncology
俄罗斯联邦, 24 Kashirskoye shosse, Moscow, 115522I. Kuznetsov
Russian University of Medicine
Email: npkredo@yandex.ru
ORCID iD: 0000-0003-0866-5501
Ph.D. (Biol.), Research Assistant
俄罗斯联邦, 4 Dolgorukovskaya ul., Moscow, 127006N. Sokolov
S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center
Email: strivp@mail.ru
ORCID iD: 0000-0002-0706-9575
Ph.D. (Med.), Head Oncology Department of Antitumor Drug Therapy
俄罗斯联邦, 5 2nd Botkinsky pr-d, Moscow, 125284S. Varfolomeeva
N.N. Blokhin National Medical Research Center of Oncology
Email: s.varfolomeeva@ronc.ru
ORCID iD: 0000-0001-6131-1783
Dr.Sc. (Med.), Professor, Director L.A. Durnov Research Institute of Pediatric Oncology and Hematology
俄罗斯联邦, 24 Kashirskoye shosse, Moscow, 115522N. Kushlinskii
Russian University of Medicine; N.N. Blokhin National Medical Research Center of Oncology
Email: biochimia@yandex.ru
ORCID iD: 0000-0002-3898-4127
Dr.Sc. (Med.), Professor, Academician of the Russian Academy of Sciences, Scientific Director of the Clinical Diagnostic Laboratory, Head of the Department of Clinical Biochemistry and Laboratory Diagnostics
俄罗斯联邦, 4 Dolgorukovskaya ul., Moscow, 127006; 24 Kashirskoye shosse, Moscow, 115522参考
- Wu H., Zhang J, Dai R. et al. Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma. J. Orthopaed. Surg. Res. 2019; 296(14): 1–5. doi: 10.1186/s13018-019-1301-z
- Dou B., Chen T., Chu Q. et al. The roles of metastasis-related proteins in the development of giant cell tumor of bone, osteosarcoma and Ewing’s sarcoma. Technol. Health Care; 29(S1): 91–101. doi: 10.3233/THC-218010
- Choi J.H., Ro J.Y. The 2020 WHO Classification of Tumors of Bone: An Updated Review. Adv. Anat. Pathol. 2021; 28(3): 119–138.
- Каприн А.Д., Старинский В.В., Петрова Г.В. (ред). Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2019. [Kaprin A.D., Starinsky V.V., Petrova G.V. (eds.). Malignant neoplasms in Russia in 2018 (morbidity and mortality). Moscow: P.A. Herzen Moscow Oncology Research Institute — branch of the National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation; 2019. (In Russ.)].
- Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022; 12(1): 31–46. doi: 10.1158/2159-8290.CD-21-1059.
- Borinstein S.C., Barkauskas D.A., Bernstein M. et al. Ana-lysis of serum insulin growth factor 1 concentrations in lo-calized osteosarcoma: A children's oncology group study. Pediatr. Blood Cancer. 2014; 61(4)749–752. doi: 10.1002/pbc.24778.
- Бабкина И.В. Алферов А.А., Бондарев А.В. и др. Клинический анализ сывороточных уровней интерлейкина-16 и фактора роста эндотелия сосудов с учетом морфологических характеристик новообразований и отдаленных результатов лечения больных опухолями костей. Альманах Клин. Мед. 2016; 44(5): 606–612. [Babkina, I.V., Alferov, A.A., Bondarev, A.V., et al. Clinical analysis of serum interleukin-16 and vascular endothelial growth factor levels depending on morphological characteristics of the tumors and long-term treatment outcomes in patients with bone neoplasms. Almanac of Clinical Medicine. 2016; 44(5): 606–612. (In Russ.)]. doi: 10.18786/2072-0505-2016-44-5-606-612.
- Chen Z., Chen Q.X., Hou Z.Y. et al. Clinical predictive value of serum angiogenic factor in patients with osteosarcoma. Asian Pac. J. Cancer Prev. 2012; 13(9): 4823–4826. doi: 10.7314/apjcp.2012.13.9.4823.
- Kim H.S., Lim S.J., Park Y.K. Anti-angiogenic factor endo-statin in osteosarcoma. APMIS. 2009; 117(10): 716–723. doi: 10.1111/j.1600-0463.2009.02524.x.
- Abd El-Rehim D.M., Osman N.A. Expression of a disintegrin and metalloprotease 8 and endostatin in human osteosarcoma: implication in tumor progression and prognosis. J. Egypt. Natl. Canc. Inst. 2015; 27(1):1–9.
- Kaya M., Wada T., Nagoya S. et al. The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma. J. Bone Joint Surg. British. 2009; 91(6): 784–788.
- Меркурьева О.Н., Бабкина И.В., Булычева И.В. и др. Клинико-лабораторное значение эндостатина в сыворотке крови подростков с саркомами костей. Технологии живых систем. 2022; 19(4): 24–32. [Merkuryeva O.N., Babkina I.V., Bulycheva I.V. et al. Clinical and laboraory significance of endostatin in the blood serum of adolescents with bone sarcomas. Technologies of Living Systems. 2022; 19(4): 24−32. (In Russ.)]. doi: 10.18127/j20700997-202204-02.
补充文件
